Equities researchers at Roth Capital started coverage on shares of Albireo Pharma, Inc. (NASDAQ:ALBO) in a research note issued to investors on Wednesday, Marketbeat reports. The firm set a “buy” rating and a $92.00 price target on the biopharmaceutical company’s stock. Roth Capital’s price target would suggest a potential upside of 253.98% from the company’s previous close.

Several other brokerages have also recently commented on ALBO. Zacks Investment Research raised Albireo Pharma from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research report on Wednesday, October 25th. Wedbush reiterated an “outperform” rating and set a $58.00 price objective on shares of Albireo Pharma in a report on Monday, September 11th. Needham & Company LLC began coverage on Albireo Pharma in a report on Tuesday, July 18th. They set a “buy” rating and a $35.00 price objective for the company. Cowen and Company began coverage on Albireo Pharma in a report on Wednesday, August 16th. They set an “outperform” rating for the company. Finally, ValuEngine lowered Albireo Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $53.75.

Albireo Pharma (NASDAQ:ALBO) traded up $0.42 on Wednesday, hitting $25.99. The stock had a trading volume of 15,800 shares, compared to its average volume of 23,793. Albireo Pharma has a 1-year low of $15.31 and a 1-year high of $37.69.

Albireo Pharma (NASDAQ:ALBO) last issued its earnings results on Monday, August 21st. The biopharmaceutical company reported ($0.86) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.02). research analysts anticipate that Albireo Pharma will post -3.6 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/18/biodel-inc-albo-earns-buy-rating-from-analysts-at-roth-capital.html.

An institutional investor recently raised its position in Albireo Pharma stock. Renaissance Technologies LLC raised its stake in shares of Albireo Pharma, Inc. (NASDAQ:ALBO) by 0.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 149,632 shares of the biopharmaceutical company’s stock after purchasing an additional 794 shares during the quarter. Renaissance Technologies LLC’s holdings in Albireo Pharma were worth $3,591,000 as of its most recent filing with the Securities and Exchange Commission. 27.29% of the stock is owned by institutional investors and hedge funds.

Albireo Pharma Company Profile

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Stock Ratings for Albireo Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma Inc. and related stocks with our FREE daily email newsletter.